CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to RGNX

Aflibercept (EYLEA®)

Phase 3
REGENXBIO Inc. (RGNX)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in AMD

View Full Landscape
Drug Information

Target Indication

AMD

Clinical Trial

NCT05407636

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.